Novel drug shows promise in an early phase trial in heart failure
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.
<p>The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.</p>